

Title (en)
COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER

Title (de)
KOMBINATION VON EGFR-HEMMER UND MEK-HEMMER ZUR VERWENDUNG BEI DER BEHANDLUNG VON NRAS-MUTIERTEM KREBS

Title (fr)
COMBINAISON D'UN INHIBITEUR DE EGFR ET UN INHIBITEUR DE MEK POUR L'UTILISATION DANS LE TRAITEMENT D'UN CANCER MUTÉ SUR NRAS

Publication
EP 3125885 B1 20210630 (EN)

Application
EP 15715805 A 20150402

Priority

- US 201461975088 P 20140404
- US 201462013573 P 20140618
- GB 2015051042 W 20150402

Abstract (en)
[origin: WO2015150826A1] The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancel- involving a gain of copy number of NRAS gene.

IPC 8 full level
A61K 31/4184 (2006.01); **A61K 31/506** (2006.01); **A61K 31/5377** (2006.01); **A61P 35/00** (2006.01)

CPC (source: CN EP KR RU US)
A61K 31/4184 (2013.01 - CN EP KR RU US); **A61K 31/4458** (2013.01 - US); **A61K 31/506** (2013.01 - CN EP KR RU US); **A61K 31/517** (2013.01 - US); **A61K 31/519** (2013.01 - US); **A61K 31/5377** (2013.01 - CN EP KR US); **A61K 45/06** (2013.01 - CN); **A61K 48/0058** (2013.01 - RU); **A61P 11/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP RU US); **A61P 43/00** (2018.01 - EP); **A61K 2300/00** (2013.01 - KR)

C-Set (source: CN EP)
1. **A61K 31/4184 + A61K 2300/00**
2. **A61K 31/506 + A61K 2300/00**
3. **A61K 31/5377 + A61K 2300/00**

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2015150826 A1 20151008; AU 2015242407 A1 20161013; AU 2015242407 B2 20171109; CA 2943402 A1 20151008; CA 2943402 C 20221213; CN 106456774 A 20170222; DK 3125885 T3 20210927; EP 3125885 A1 20170208; EP 3125885 B1 20210630; ES 2890556 T3 20220120; HU E055747 T2 20211228; JP 2017511341 A 20170420; JP 6549147 B2 20190724; KR 102406334 B1 20220607; KR 20160135362 A 20161125; MA 39841 A 20170208; MX 2016013048 A 20170427; MX 369111 B 20191029; PL 3125885 T3 20211206; RU 2016140626 A 20180507; RU 2016140626 A3 20181023; RU 2683276 C2 20190327; US 2020237758 A1 20200730; US 2021177844 A1 20210617

DOCDB simple family (application)
GB 2015051042 W 20150402; AU 2015242407 A 20150402; CA 2943402 A 20150402; CN 201580022665 A 20150402; DK 15715805 T 20150402; EP 15715805 A 20150402; ES 15715805 T 20150402; HU E15715805 A 20150402; JP 2016560813 A 20150402; KR 20167030569 A 20150402; MA 39841 A 20150402; MX 2016013048 A 20150402; PL 15715805 T 20150402; RU 2016140626 A 20150402; US 201515301448 A 20150402; US 202017123777 A 20201216